SREBF1 and fatty liver disease: Supplementation with 0.1% I3C in HFD ameliorated hepatic steatosis, achieved through marked suppression of SREBP1-regulated lipogenic enzyme expression, and subsequent attenuation of hepatic lipid accumulation [24].